
Synlogic (SYBX) Stock Forecast & Price Target
Synlogic (SYBX) Analyst Ratings
Bulls say
Synlogic Inc. operates in the biopharmaceutical sector, focusing on pioneering treatments for rare metabolic disorders, particularly phenylketonuria (PKU) and homocystinuria (HCU), using a proprietary platform that employs engineered probiotics. The company has a robust pipeline, including therapeutics for conditions such as enteric hyperoxaluria, gout, and cystinuria, which could potentially enhance its market position and financial metrics over time. With trading at approximately one-third of its cash reserves, Synlogic's current valuation may present an opportunity for future growth contingent on strategic decisions that can support its operational continuity and attract new investment.
Bears say
Synlogic Inc. reported a significant net loss of $14.5 million for the fourth quarter of 2023, equating to a loss of $1.71 per share, reflecting the company's financial struggles. The early termination of the Synpheny-3 trial due to efficacy futility has led to a drastic reduction in operations, including an over 90% workforce cut and the exit of key leadership, notably the CEO. These developments indicate substantial challenges in advancing Synlogic's pipeline and suggest a diminished capacity for future growth in the biopharmaceutical sector focused on rare metabolic disorders.
This aggregate rating is based on analysts' research of Synlogic and is not a guaranteed prediction by Public.com or investment advice.
Synlogic (SYBX) Analyst Forecast & Price Prediction
Start investing in Synlogic (SYBX)
Order type
Buy in
Order amount
Est. shares
0 shares